2025
SJR Q2
JCR Q2 · 2,2
145 matched articles
SCIE
Journal detail
Journal of Ocular Pharmacology and Therapeutics
- Publisher
- Mary Ann Liebert Inc.
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
1080768315577732
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,621
- Quartile Q2
- H-Index 81
- Cites/doc 2,13
- Docs (3y) 252
- Cites (3y) 616
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,2
- 5Y JIF 2,6
- JCI 0,67
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Ophthalmology Q2
- Pharmacology Q2
- Pharmacology (medical) Q2
Areas
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Ophthalmology | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,621 | 2,2 | 2,6 | 0,67 | Q2 | 81 |
| 2024 | Q2 | Q2 | 0,597 | 2,1 | 2,3 | 0,69 | Q2 | 76 |
| 2023 | Q2 | Q2 | 0,599 | 1,9 | 3,4 | 0,81 | Q2 | 76 |
| 2022 | Q2 | Q3 | 0,472 | 2,3 | 2,3 | 0,75 | Q2 | 76 |
| 2021 | Q2 | Q3 | 0,58 | 2,9 | 2,8 | 0,89 | Q2 | 76 |
| 2020 | Q2 | Q2 | 0,727 | 2,7 | 2,4 | 0,81 | Q2 | 76 |
| 2019 | Q2 | Q3 | 0,65 | 2 | 1,8 | 0,75 | Q2 | 76 |
| 2018 | — | Q3 | — | 1,8 | 2 | 0,67 | Q2 | — |
| 2017 | Q2 | Q3 | 0,8 | 1,9 | 2 | 0,65 | Q3 | 76 |
| 2016 | Q2 | Q3 | 0,685 | 1,7 | 1,7 | — | — | 76 |
| 2015 | Q2 | Q2 | 0,751 | 1,8 | 1,7 | — | — | 76 |
| 2014 | Q2 | Q3 | 0,791 | 1,5 | 1,6 | — | — | 76 |
| 2013 | Q2 | Q3 | 0,804 | 1,4 | 1,5 | — | — | 76 |
| 2012 | Q2 | Q3 | 0,785 | 1,3 | 1,3 | — | — | 76 |
| 2011 | Q2 | Q2 | 0,726 | 1,5 | 1,6 | — | — | 76 |
| 2010 | Q2 | Q2 | 0,718 | 1,6 | 1,6 | — | — | 76 |
| 2009 | — | Q3 | — | 1,5 | 1,4 | — | — | — |
| 2008 | — | Q3 | — | 1,4 | 1,4 | — | — | — |
| 2007 | — | Q3 | — | 1 | 1,2 | — | — | — |
| 2006 | — | Q3 | — | 1 | — | — | — | — |
| 2005 | — | Q3 | — | 0,9 | — | — | — | — |
| 2004 | — | Q2 | — | 1,2 | — | — | — | — |
| 2003 | — | Q2 | — | 1,4 | — | — | — | — |
| 2002 | — | Q3 | — | 1,1 | — | — | — | — |
| 2001 | — | Q2 | — | 1,1 | — | — | — | — |
| 2000 | — | Q3 | — | 0,8 | — | — | — | — |
| 1999 | — | Q2 | — | 0,8 | — | — | — | — |
| 1998 | — | Q2 | — | 0,8 | — | — | — | — |
| 1997 | — | Q2 | — | 0,8 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | OPHTHALMOLOGY | SCIE | Q2 | Q3 | 43/98 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 231/356 |
| 2024 | OPHTHALMOLOGY | SCIE | Q2 | Q3 | 39/99 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 222/352 |
| 2023 | OPHTHALMOLOGY | SCIE | Q2 | Q2 | 45/95 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 231/354 |
| 2022 | OPHTHALMOLOGY | SCIE | Q3 | Q2 | 32/62 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 200/278 |
| 2021 | OPHTHALMOLOGY | SCIE | Q3 | Q2 | 33/62 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 186/279 |
| 2020 | OPHTHALMOLOGY | SCIE | Q2 | Q2 | 31/62 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 184/276 |
| 2019 | OPHTHALMOLOGY | SCIE | Q3 | Q2 | 31/60 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 198/271 |
| 2018 | OPHTHALMOLOGY | SCIE | Q3 | Q2 | 31/60 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 196/267 |
| 2017 | OPHTHALMOLOGY | SCIE | Q3 | Q3 | 30/59 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 179/261 |
| 2016 | OPHTHALMOLOGY | SCIE | Q3 | — | 37/59 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 188/257 |
| 2015 | OPHTHALMOLOGY | SCIE | Q2 | — | 28/56 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 169/255 |
| 2014 | OPHTHALMOLOGY | SCIE | Q3 | — | 33/57 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 185/255 |
| 2013 | OPHTHALMOLOGY | SCIE | Q3 | — | 34/58 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 178/256 |
| 2012 | OPHTHALMOLOGY | SCIE | Q3 | — | 37/59 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 190/261 |
| 2011 | OPHTHALMOLOGY | SCIE | Q2 | — | 28/58 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 181/261 |
| 2010 | OPHTHALMOLOGY | SCIE | Q2 | — | 25/56 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 170/252 |
| 2009 | OPHTHALMOLOGY | SCIE | Q3 | — | 27/49 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 166/237 |
| 2008 | OPHTHALMOLOGY | SCIE | Q3 | — | 25/48 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 160/219 |
| 2007 | OPHTHALMOLOGY | SCIE | Q3 | — | 32/45 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 164/205 |
| 2006 | OPHTHALMOLOGY | SCIE | Q3 | — | 30/45 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 155/199 |
| 2005 | OPHTHALMOLOGY | SCIE | Q3 | — | 30/44 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 159/193 |
| 2004 | OPHTHALMOLOGY | SCIE | Q2 | — | 20/42 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 127/187 |
| 2003 | OPHTHALMOLOGY | SCIE | Q2 | — | 16/41 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 111/185 |
| 2002 | OPHTHALMOLOGY | SCIE | Q3 | — | 21/41 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 124/188 |
| 2001 | OPHTHALMOLOGY | SCIE | Q2 | — | 20/43 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 115/186 |
| 2000 | OPHTHALMOLOGY | SCIE | Q3 | — | 22/41 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 142/181 |
| 1999 | OPHTHALMOLOGY | SCIE | Q2 | — | 21/43 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 122/175 |
| 1998 | OPHTHALMOLOGY | SCIE | Q2 | — | 18/42 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 107/178 |
| 1997 | OPHTHALMOLOGY | SCIE | Q2 | — | 18/39 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 111/157 |